About Us

Duchesnay Pharmaceutical Group's structure

are driven by the belief that women's health is the key to the success of the societies they are part of, enabling each woman to reach her full potential. In practical terms, we strive to provide safe and effective therapies to ensure quality of life for women and their families at all stages of their life.

makes available innovative treatments to those affected by rare diseases in line with our deep belief that wellbeing should be accessible to everyone without exception.

are built on the idea that health should not depend on price, which motivates us to move forward in our quest to offer the highest quality remedies at reasonable prices for all those whose lives are affected by disease.

Mission

The mission of DPG is based on our deep conviction that by promoting the well-being of each individual we contribute to the well-being of society as a whole. This mission guides us to invest all our efforts in the research and development of innovative treatments for a variety of medical conditions.

Vision

We, at Duchesnay Pharmaceutical Group, choose to broaden our horizons and challenge the impossible to offer cutting-edge therapeutic solutions to patients by investing our hearts, minds, and all our resources in the never-ending processes of innovation, development and improvement of our products aimed to create better conditions for everyone so every individual can reach their full potential.

Values

The corporate culture of Duchesnay Pharmaceutical Group is based on four core values: excellence, integrity, innovation, and collaboration, which are concrete tools that help us ensure access to our most effective and innovative health solutions.

Excellence

In order to guarantee our customers high quality medicines, we have implemented a system of constant evaluation of each stage of production, together with the continuous training of our employees to maintain the highest standards of professionalism within the DPG.

Integrity

At Duchesnay Pharmaceutical Group, integrity is maintained through frank and continuous dialogue between the executive team and employees, as well as through the transparency of our work policies and our corporate strategies supported by openness towards our clients and partners.

Innovation

Proud of the products we offer, we never stop innovating and invest in research and development in order to present new and better treatment options to improve the health of every individual at every stage of his/her life.

Collaboration

Our corporate culture is based on team spirit, valuing individual talents, expertise and strengths while encouraging contribution to common success. The same principles guide the relationships with DPG's partners and clients.

Our Executive Team

Éric Gervais

President

A visionary of DPG, Eric has led the company for over 30 years. With a bachelor’s degree in biology, he is an inventor of more than 6 patents owned by the Group, many of which have been approved in over 40 countries. His desire to advance science by shaping the environment to ensure access to treatment, combined with his professionalism, keeps DPG on the path to success.

The idea is to build a sustainable business that offers hope to all those who are affected by a disease.

Tanya Carro

Executive Vice President, U.S. Entities

A steward of growth for all of DPG's U.S. entities, Tanya has over 30 years of experience in the life sciences industry. Her strong and broad expertise spans finance, operations, business development, strategic planning, mergers and acquisitions, and management of multi-site teams. Her focused, strategic and human approach allows Tanya to turn new challenges into opportunities.

I couldn’t ask for a better team to work with. We share common goals and are able to accomplish great things together.

Michael Gallo

Vice-president, Regulatory and Medical Affairs

A strategic thinker and the architect of DPG’s unique regulatory approach, Michael has nearly 25 years of in-depth experience in the development and licensing of innovative medicinal products. His extensive expertise and enthusiasm in leading his team are fundamental to our ability to navigate through various medical-regulatory systems nationally and internationally. Michael is proud of his team’s accomplishments and excited for what the future holds:

There are no limitations at DPG. Working globally on products from various therapeutic classes is what drives us and keeps the work interesting.

Dany Hallé

Vice-president, Commercial Affaires

The driving force behind DPG's commercial success, Dany holds multiple university degrees in science, including a Master in Molecular Genetics and a Bachelor in Microbiology. In addition, he has recently completed a CMAP certification in Market Access. His expertise combined with years long experience in sales, marketing and market access in the pharmaceutical industry makes Dany unique when it comes to conquering new markets, leading his teams with collegiality and innovation always geared towards excellence.

The risk-taking / entrepreneur mindset is encouraged and there is no fear of making mistakes along the way as we learn by making these and grow better and faster.

Manon Vranderick

Vice President, Product Development & Manufacturing Strategy

A pillar of all production, quality, and distribution functions at DPG, Manon has a strong and rare combination of skills in multi-site pharmaceutical research, operations management, new product development, and management of large teams, both directly and through relationships with international partners. With over 35 years in the pharmaceutical industry, she has dedicated over 12 years to DPG's success.

Keeping a family and entrepreneurial approach we are building on our strong foundations to pursue our international growth. It allows me and my teams to thrive and learn from global and ever-evolving challenges every day.

Mélanie Therrien

Vice President, Finance & Corporate Affairs

With more than 25 years of experience in helping companies achieve financial health, Mélanie is the quiet force of the team who leads with enthusiasm her teams to excellence. Her expertise in accounting and taxation combined with her work ethic and ability to build trusting relationships explain how financial health has become everyone's responsibility at DPG.

We work with professionals who want to excel and bring Duchesnay Pharmaceutical Group further. It is very inspiring.

Caroline Guerru

Vice-president, Human Resources and Communications

A driving force behind flexibility and talent development at DPG, Caroline has over 20 years of strategic human resources management experience in the pharmaceutical industry. The work strategies she has adopted at DPG have consolidated the foundations of the Group's team by transforming it into a professional family where everyone's natural gifts are appreciated. This approach of closeness, agility and transparency carries over into her role as Communications Leader.

What sets us apart I would say is our culture, which I would describe as human, flexible and entrepreneurial. Also, the objectives we are setting to achieve while involving everyone keeps us all motivated and constantly growing.

Suzanne Paszkiewicz

Vice President, Global Partnerships & Business Development

A driver of DPG’s international growth, Suzanne, cumulating a 30-year career in the pharmaceutical industry, has succeeded in multiple roles. Her main strengths are piloting strategy to execution and leading cross-functional teams towards success. Suzanne’s mission at DPG is to strengthen the Group’s international positioning and bring the Group to the next level of collaboration with international partners.

I can say that every Duchesnay Pharmaceutical Group’s team member I have met exemplifies a shared passion and commitment to the mission of DPG, with ambition to continually improve options for patients, in a highly "all-in" & collaborative environment.

DPG’s history

1970

Duchesnay Pharmaceutical Group (DPG) originated in the 70s when Louis Boivin acquired Duchesnay, a family business involved in the distribution of drugs in Quebec pharmacies. The pharmaceutical industry in Canada was then on the cusp of major changes that would materialize over the coming decades.

1990

With the arrival of Éric Gervais in 1992, the company widens its field of activity and invests in the research and development of innovative treatments, intended specifically for pregnant women and their unborn children. The publication of numerous studies testifies to Duchesnay's commitment to developing safe and effective drugs during pregnancy and to making cutting-edge medical information accessible.

Duchesnay’s team works with the medical community, both in Canada and abroad, to have a medical condition recognized, until now ignored as such: nausea and vomiting of pregnancy (NVP). In 1998, they organize the first International Conference on NVP, bringing together a panel of obstetrical experts from all over the world. Mission accomplished, the conference is a success and NVP is now a world-recognized medical condition.

2000

The company is active in advancing maternal-fetal medicine. It innovates and develops various drugs, including Pregvit and Pregvit folic 5. These innovative formulations are the result of a long process of research and development, specially developed and adapted to the unique needs of women, before, during and after pregnancy.

At the same time, the Quebec-based SME files several patents in more than 40 countries for innovations resulting from its research and development activities.

2009

True to its mission to improve the health and quality of life of patients, management founds Medunik Canada, dedicated to better meet the needs of Canadians living with a rare disease. Its turnkey business model, based on licensing, provides patients with access to orphan drugs available elsewhere in the world. The company works closely with medical communities specializing in inheredited metabolic diseases corresponding to the indication of each of its drugs.

The global patent portfolio grows at a fast pace, reaffirming the company's commitment to improving health and supporting the development of patients around the world. With that in mind, the company sets up its own manufacturing plant and inaugurates its new facilities and head office in Blainville, Quebec, at the turn of the decade. Since then, Duchesnay proudly manufactures, right here in Quebec, its drugs for both Canada and export.

2012

and

2013

Years of many challenges! The multinational is born with the establishment of Duchesnay USA in 2012. The American team develops its marketing strategy while awaiting the FDA’s approval for its flagship drug which has been approved for the Canadian market for many decades. From April 2013, Duchesnay exports its know-how to the United States. To this day, Duchesnay remains one of the few Canadian pharmaceutical companies to have successfully entered the American market.

2017

Medunik Canada extends its business model to the United States under Medunik USA. Thanks to its strategic partnerships, Medunik USA markets orphan drugs available abroad to fill the gap in therapeutic solutions for Americans living with a rare disease.

2018

Set on offering generic drugs of the highest quality, the multinational founds Analog Pharma in the United States. The company focuses its activities on the production and distribution of generic and ultra-generic pharmaceutical products, identical to brand name drugs in the segments of women's health and rare diseases. The multinational now has three American companies.

2021

The management team acquires Duchesnay, its four affiliated pharmaceutical companies and its manufacturing plant, now united under the banner Duchesnay Pharmaceutical Group. From its head office and manufacturing plant in Blainville, Quebec, the multinational DPG proudly pursues its mission in North America and abroad: Duchesnay, based in Canada, and Duchesnay USA, both dedicated to women's health; Medunik Canada and Medunik USA, for the treatment of rare diseases; and Analog Pharma, an American generic drug company, specializing in orphan drugs.

2022

Phenomenal year! The Group launches five new drugs: three in women's health in Canada and two orphan drugs in the United States. The year ends with more than 20 new regulatory approvals in women's health around the world.

2023

All sectors of activity of Duchesnay Pharmaceutical Group are in tune and the excitement is palpable. Abroad, the number of regulatory approvals continues to grow for its innovations in women’s health and exports take off. Already, the production team is stepping up to meet the demand. Since July 24th, the Group has officially been part of the first cohort selected for the Global Hypergrowth Project (GHP), a pioneering initiative of the federal government. This nomination positions DPG among Canadian companies with high growth potential and as future pillar of the Canadian economy. It goes without saying that everyone at DPG is enthusiastic to continue the growth of the Group, in partnership with the GHP.

2024

January 1

New year – new entity! Duchesnay Pharmaceutical Group welcomes Analog Pharma Canada, a new member dedicated to providing quality orphan generic medications at affordable prices and allowing Canadian patients to benefit from our unique expertise by distributing “ultra-generic” versions of our flagship products.

June 5

DPG awarded Parity Certification^TM by Women in Governance.

October 16

Éric GERVAIS, President of DPG, named the laureate of the 2024 Bernard-Landry Award by the Association for the Development of Research and Innovation of Quebec (ADRIQ).

November 21

DPG receives the 2024 Life Sciences Innovation Award from the Association for the Development of Research and Innovation of Quebec (ADRIQ).